Caribou Biosciences

CRBU

Market cap $159M

1.70 USD

-0.02

1.16%

At close Updated Dec 26, 4:00 PM EST

Pre-market

After hours

1.66

-0.04

2.35%

1 day

-1.16%

5 days

3.66%

1 month

-9.57%

3 months

-20.19%

6 months

25.93%

Year to date

1.19%

1 year

5 years

-89.58%

10 years

-89.58%

About: Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Employees: 147

Healthcare Biotechnology